Lipoprotein-associated phospholipase A2, C-reactive protein, and coronary artery disease in individuals with type 1 diabetes and macroalbuminuria

被引:18
作者
Miller, Rachel G. [1 ]
Costacou, Tina [1 ]
Orchard, Trevor J. [1 ]
机构
[1] Univ Pittsburgh, Dept Epidemiol, Grad Sch Publ Hlth, Pittsburgh, PA 15213 USA
基金
美国国家卫生研究院;
关键词
Lp-PLA(2); type; 1; diabetes; macroalbuminuria; coronary artery disease; C-reactive protein; haptoglobin genotype; PLATELET-ACTIVATING-FACTOR; CARDIOVASCULAR RISK-FACTORS; APPARENTLY HEALTHY-MEN; MIDDLE-AGED MEN; HEART-DISEASE; FACTOR-ACETYLHYDROLASE; PITTSBURGH EPIDEMIOLOGY; FOLLOW-UP; MYOCARDIAL-INFARCTION; INDEPENDENT PREDICTOR;
D O I
10.1177/1479164109346358
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Given the paucity of data in type 1 diabetes concerning lipoprotein-associated phospholipase A(2) (Lp-PLA(2)), we examined its prospective relationship with coronary artery disease (CAD), as well as the effect of modification by C-reactive protein (CRP) and haptoglobin genotype, in individuals with type 1 diabetes who are at an increased risk for CAD due to also having macroalbuminuria (n=96). Although Lp-PLA(2) activity was univariately predictive of CAD (HR=1.54 per SD, p=0.009), this relationship was not significant after covariate adjustment (p=0.59). There was a significant interaction between Lp-PLA(2) and CRP (p=0.02), i.e. those with both markers greater than the median level were more likely to have a CAD event than those persons with low levels of both (HR=2.89, p=0.06). When stratified by haptoglobin genotype, Lp-PLA(2) was predictive of CAD in persons with the 2/1 (HR=2.40, p=0.05), but not 2/2 (HR=0.66, p=0.27), genotype. The association between Lp-PLA(2) activity and CAD differs by CRP and haptoglobin genotype in this group of persons with type 1 diabetes and macroalbuminuria.
引用
收藏
页码:47 / 55
页数:9
相关论文
共 59 条
[1]  
ALLAIN CC, 1974, CLIN CHEM, V20, P470
[2]   The association between lipoprotein-associated phospholipase A2 and cardiovascular disease and total mortality in vascular medicine patients [J].
Allison, Matthew A. ;
Denenberg, Julie O. ;
Nelson, Jeanenne J. ;
Natarajan, Loki ;
Criqui, Michael H. .
JOURNAL OF VASCULAR SURGERY, 2007, 46 (03) :500-506
[3]  
[Anonymous], 1976, PREV MED, V5, P207, DOI DOI 10.1016/0091-7435(76)90039-6
[4]   Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study [J].
Ballantyne, CM ;
Hoogeveen, RC ;
Bang, H ;
Coresh, J ;
Folsom, AR ;
Heiss, G ;
Sharrett, AR .
CIRCULATION, 2004, 109 (07) :837-842
[5]   A prospective evaluation of lipoprotein-associated phospholipase A2 levels and the risk of future cardiovascular events in women [J].
Blake, GJ ;
Dada, N ;
Fox, JC ;
Manson, JE ;
Ridker, PM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 38 (05) :1302-1306
[6]   Physical activity, C-reactive protein levels and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk prospective population study [J].
Boekholdt, S. Matthijs ;
Sandhu, Manjinder S. ;
Day, Nicholas E. ;
Luben, Robert ;
Bingham, Sheila A. ;
Peters, Ron J. G. ;
Wareham, Nicholas J. ;
Khaw, Kay-Tee .
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION, 2006, 13 (06) :970-976
[7]   Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up [J].
Brilakis, ES ;
McConnell, JP ;
Lennon, RJ ;
Elesber, AA ;
Meyer, JG ;
Berger, PB .
EUROPEAN HEART JOURNAL, 2005, 26 (02) :137-144
[8]  
BUCOLO G, 1973, CLIN CHEM, V19, P476
[9]   Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-inducing effects of oxidised LDL on human monocyte-macrophages [J].
Carpenter, KLH ;
Dennis, IF ;
Challis, IR ;
Osborn, DP ;
Macphee, CH ;
Leake, DS ;
Arends, MJ ;
Mitchinson, MJ .
FEBS LETTERS, 2001, 505 (03) :357-363
[10]   Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase:: a potential new risk factor for coronary artery disease [J].
Caslake, MJ ;
Packard, CJ ;
Suckling, KE ;
Holmes, SD ;
Chamberlain, P ;
Macphee, CH .
ATHEROSCLEROSIS, 2000, 150 (02) :413-419